Said M. Sebti - Publications

University of South Florida, Tampa, FL, United States 
Biochemistry, Cell Biology

170 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, Sebti SM, Malafa MP. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. The Journal of Nutritional Biochemistry. 26: 797-807. PMID 25997867 DOI: 10.1016/j.jnutbio.2015.02.008  1
2015 Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of Leukocyte Biology. 97: 807-19. PMID 25663681 DOI: 10.1189/jlb.5A1114-532RR  1
2015 Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, Li J, Qin Y, Gavathiotis E, Sebti SM. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry. 90: 315-31. PMID 25437618 DOI: 10.1016/j.ejmech.2014.11.035  1
2014 Tecleab A, Zhang X, Sebti SM. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. The Journal of Biological Chemistry. 289: 31296-309. PMID 25210032 DOI: 10.1074/jbc.M114.565796  1
2014 Kim YB, Kang CW, Ranatunga S, Yang H, Sebti SM, Del Valle JR. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt. Bioorganic & Medicinal Chemistry Letters. 24: 4650-3. PMID 25205195 DOI: 10.1016/j.bmcl.2014.08.040  1
2014 Cheng C, Liu Y, Balasis ME, Garner TP, Li J, Simmons NL, Berndt N, Song H, Pan L, Qin Y, Nicolaou KC, Gavathiotis E, Sebti SM, Li R. Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim. Marine Drugs. 12: 4311-25. PMID 25076060 DOI: 10.3390/md12084311  1
2013 Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM. Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. Plos One. 8. PMID 24205284  1
2009 Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (Georgetown, Tex.). 8: 1940-51. PMID 19471122  1
2009 Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC. Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking. Bioorganic & Medicinal Chemistry Letters. 19: 3756-9. PMID 19457663 DOI: 10.1016/j.bmcl.2009.04.124  1
2009 Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology. 16: 181-92. PMID 19246009 DOI: 10.1016/j.chembiol.2009.01.014  1
2009 Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Molecular and Cellular Biology. 29: 2254-63. PMID 19204084 DOI: 10.1128/MCB.01029-08  1
2009 Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorganic & Medicinal Chemistry. 17: 1764-71. PMID 19179081 DOI: 10.1016/j.bmc.2008.09.058  1
2008 Gunning PT, Glenn MP, Siddiquee KA, Katt WP, Masson E, Sebti SM, Turkson J, Hamilton AD. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem : a European Journal of Chemical Biology. 9: 2800-3. PMID 19006150 DOI: 10.1002/cbic.200800291  1
2008 Fletcher S, Cummings CG, Rivas K, Katt WP, Hornéy C, Buckner FS, Chakrabarti D, Sebti SM, Gelb MH, Van Voorhis WC, Hamilton AD. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. Journal of Medicinal Chemistry. 51: 5176-97. PMID 18686940 DOI: 10.1021/jm800113p  1
2008 Lawrence HR, Pireddu R, Chen L, Luo Y, Sung SS, Szymanski AM, Yip ML, Guida WC, Sebti SM, Wu J, Lawrence NJ. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. Journal of Medicinal Chemistry. 51: 4948-56. PMID 18680359 DOI: 10.1021/jm8002526  1
2008 Gustafsdottir SM, Wennström S, Fredriksson S, Schallmeiner E, Hamilton AD, Sebti SM, Landegren U. Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors. Clinical Chemistry. 54: 1218-25. PMID 18499900 DOI: 10.1373/clinchem.2007.099424  1
2008 Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, Lawrence N, Sebti SM, Chellappan S. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Research. 68: 3810-8. PMID 18483265 DOI: 10.1158/0008-5472.CAN-07-6672  1
2008 Machida S, Usuba K, Blaskovich MA, Yano A, Harada K, Sebti SM, Kato N, Ohkanda J. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces. Chemistry (Weinheim An Der Bergstrasse, Germany). 14: 1392-401. PMID 18200641 DOI: 10.1002/chem.200701634  1
2008 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity (Oncogene (2005) 24, (3236-3245) DOI: 10.1038/sj.onc.1208470) ) Oncogene. 27: 1344. DOI: 10.1038/sj.onc.1211028  1
2007 Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. Acs Chemical Biology. 2: 787-98. PMID 18154266 DOI: 10.1021/cb7001973  1
2007 Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Molecular and Cellular Biology. 27: 8003-14. PMID 17875936 DOI: 10.1128/MCB.00057-07  1
2007 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 7391-6. PMID 17463090 DOI: 10.1073/pnas.0609757104  1
2007 Gunning PT, Katt WP, Glenn M, Siddiquee K, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorganic & Medicinal Chemistry Letters. 17: 1875-8. PMID 17336521 DOI: 10.1016/j.bmcl.2007.01.077  1
2007 Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I Bioorganic and Medicinal Chemistry Letters. 17: 2639-2642. PMID 17314046 DOI: 10.1016/j.bmcl.2007.01.097  1
2007 Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorganic & Medicinal Chemistry Letters. 17: 2068-73. PMID 17276059 DOI: 10.1016/j.bmcl.2007.01.004  1
2007 Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26: 3777-88. PMID 17260025 DOI: 10.1038/sj.onc.1210172  1
2007 Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Corrigendum to "Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I" [Bioorg. Med. Chem. Lett. 17 (2007) 2639-2642] (DOI:10.1016/j.bmcl.2007.01.097) Bioorganic and Medicinal Chemistry Letters. 17: 5492. DOI: 10.1016/j.bmcl.2007.07.042  1
2007 Gunning PT, Katt WP, Glenn M, Siddiquee K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Corrigendum to "Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains" [Bioorg. Med. Chem. Lett. 17 (2007) 1875-1878] (DOI:10.1016/j.bmcl.2007.01.077) Bioorganic and Medicinal Chemistry Letters. 17: 2949. DOI: 10.1016/j.bmcl.2007.03.063  1
2006 Glenn MP, Chang SY, Hornéy C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. Journal of Medicinal Chemistry. 49: 5710-27. PMID 16970397 DOI: 10.1021/jm060081v  1
2006 Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. The Journal of Biological Chemistry. 281: 33030-5. PMID 16905541 DOI: 10.1074/jbc.C600147200  1
2006 Zhou H, Wang DA, Baldini L, Ennis E, Jain R, Carie A, Sebti SM, Hamilton AD. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Organic & Biomolecular Chemistry. 4: 2376-86. PMID 16763682 DOI: 10.1039/b515483a  1
2006 Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences. 79: 1484-92. PMID 16740276 DOI: 10.1016/j.lfs.2006.04.019  1
2006 Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology. 70: 562-70. PMID 16717135 DOI: 10.1124/mol.106.025536  1
2006 Peng H, Carrico D, Thai V, Blaskovich M, Bucher C, Pusateri EE, Sebti SM, Hamilton AD. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Organic & Biomolecular Chemistry. 4: 1768-84. PMID 16633570 DOI: 10.1039/b517572k  1
2006 Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Molecular Cancer Therapeutics. 5: 309-16. PMID 16505104 DOI: 10.1158/1535-7163.MCT-05-0330  1
2006 Ohkanda J, Strickland CL, Blaskovich MA, Carrico D, Lockman JW, Vogt A, Bucher CJ, Sun J, Qian Y, Knowles D, Pusateri EE, Sebti SM, Hamilton AD. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry. 4: 482-92. PMID 16446806 DOI: 10.1039/b508184j  1
2005 Guida WC, Hamilton AD, Crotty JW, Sebti SM. Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling. Journal of Computer-Aided Molecular Design. 19: 871-85. PMID 16607571 DOI: 10.1007/s10822-005-9030-2  1
2005 Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research. 65: 9525-35. PMID 16230418 DOI: 10.1158/0008-5472.CAN-05-0529  1
2005 Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM, Youle RJ, Wang HG. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Molecular and Cellular Biology. 25: 9369-82. PMID 16227588 DOI: 10.1128/MCB.25.21.9369-9382.2005  1
2005 Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, Gabrilovich DI. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology (Baltimore, Md. : 1950). 175: 4338-46. PMID 16177074  1
2005 Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP, Ernst JT, Wang HG, Sebti SM, Hamilton AD. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. Journal of the American Chemical Society. 127: 10191-6. PMID 16028929 DOI: 10.1021/ja050122x  1
2005 Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24: 4701-9. PMID 15897913 DOI: 10.1038/sj.onc.1208391  1
2005 Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 7: 297-300. PMID 15837619 DOI: 10.1016/j.ccr.2005.04.005  1
2005 Yin H, Lee GI, Sedey KA, Rodriguez JM, Wang HG, Sebti SM, Hamilton AD. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Journal of the American Chemical Society. 127: 5463-8. PMID 15826183 DOI: 10.1021/ja0446404  1
2005 Yin H, Lee GI, Park HS, Payne GA, Rodriguez JM, Sebti SM, Hamilton AD. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angewandte Chemie (International Ed. in English). 44: 2704-7. PMID 15765497 DOI: 10.1002/anie.200462316  1
2005 Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research. 304: 354-64. PMID 15748883 DOI: 10.1016/j.yexcr.2004.10.019  1
2005 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24: 3236-45. PMID 15735720 DOI: 10.1038/sj.onc.1208470  1
2005 Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-66. PMID 15728126 DOI: 10.1182/blood-2004-11-4307  1
2005 Wang DA, Sebti SM. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. The Journal of Biological Chemistry. 280: 19243-9. PMID 15713677 DOI: 10.1074/jbc.M411472200  1
2005 Carrico D, Blaskovich MA, Bucher CJ, Sebti SM, Hamilton AD. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry. 13: 677-88. PMID 15653335 DOI: 10.1016/j.bmc.2004.10.053  1
2005 Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, Stern PH. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochemical Pharmacology. 69: 87-95. PMID 15588717 DOI: 10.1016/j.bcp.2004.08.036  1
2004 Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry. 12: 6517-26. PMID 15556768 DOI: 10.1016/j.bmc.2004.09.020  1
2004 Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP. Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Molecular and Cellular Biology. 24: 9527-41. PMID 15485920 DOI: 10.1128/MCB.24.21.9527-9541.2004  1
2004 Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, ... Sebti SM, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7: 75-85. PMID 15302999 DOI: 10.1023/  1
2004 Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research. 64: 4394-9. PMID 15231645 DOI: 10.1158/0008-5472.CAN-04-0343  1
2004 Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Research. 64: 3586-92. PMID 15150116 DOI: 10.1158/0008-5472.CAN-03-2673  1
2004 Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Seminars in Oncology. 31: 28-39. PMID 14981578  1
2004 Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 23: 706-15. PMID 14737105 DOI: 10.1038/sj.onc.1207171  1
2004 Jiang K, Delarue FL, Sebti SM. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation Oncogene. 23: 1136-1145. PMID 14647415 DOI: 10.1038/sj.onc.1207236  1
2003 Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Current Opinion in Investigational Drugs (London, England : 2000). 4: 1428-35. PMID 14763128  1
2003 Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews. Cancer. 3: 945-51. PMID 14737124 DOI: 10.1038/nrc1234  1
2003 Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Research. 63: 8922-9. PMID 14695209  1
2003 Sebti SM. Blocked Pathways: FTIs Shut Down Oncogene Signals Oncologist. 8: 30-38. PMID 14671226  1
2003 Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents. Progress in Cell Cycle Research. 5: 211-7. PMID 14593715  1
2003 Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene. 22: 6257-65. PMID 13679864 DOI: 10.1038/sj.onc.1206630  1
2003 Forsberg M, Blomgran R, Lerm M, Särndahl E, Sebti SM, Hamilton A, Stendahl O, Zheng L. Differential effects of invasion by and phagocytosis of Salmonella typhimurium on apoptosis in human macrophages: Potential role of Rho-GTPases and Akt Journal of Leukocyte Biology. 74: 620-629. PMID 12960245 DOI: 10.1189/jlb.1202586  1
2003 Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 102: 4527-34. PMID 12947010 DOI: 10.1182/blood-2002-11-3359  1
2003 Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research. 63: 1270-9. PMID 12649187  1
2003 Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 17: 451-7. PMID 12592346 DOI: 10.1038/sj.leu.2402832  1
2003 Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology. 144: 989-98. PMID 12586776 DOI: 10.1210/en.2002-220726  1
2003 Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Molecular Pharmacology. 63: 159-66. PMID 12488548 DOI: 10.1124/mol.63.1.159  1
2002 Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle (Georgetown, Tex.). 1: 430-7. PMID 12548020  1
2002 Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 21: 8486-97. PMID 12466968 DOI: 10.1038/sj.onc.1205946  1
2002 Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Muñoz-Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2225-32. PMID 12114424  1
2002 Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death and Differentiation. 9: 702-9. PMID 12058275 DOI: 10.1038/sj.cdd.4401023  1
2002 Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Current Topics in Medicinal Chemistry. 2: 303-23. PMID 11944822  1
2002 Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 168: 4087-94. PMID 11937568  1
2002 Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. The Journal of Biological Chemistry. 277: 15309-16. PMID 11839765 DOI: 10.1074/jbc.M201253200  1
2002 Ohkanda J, Lockman JW, Kothare MA, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. Journal of Medicinal Chemistry. 45: 177-88. PMID 11754590 DOI: 10.1021/jm0103099  1
2002 Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Muñoz-Antonia T. Rhob, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1 Journal of Biological Chemistry. 277: 8500-8507. PMID 11741970 DOI: 10.1074/jbc.M104367200  1
2001 Kucich U, Rosenbloom JC, Herrick DJ, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. Archives of Biochemistry and Biophysics. 395: 103-12. PMID 11673871 DOI: 10.1006/abbi.2001.2571  1
2001 Delarue FL, Taylor BS, Sebti SM. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells Oncogene. 20: 6531-6537. PMID 11641777 DOI: 10.1038/sj.onc.1204801  1
2001 Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Sebti SM. Signal transduction pathways of IL-1beta-mediated iNOS in pulmonary vascular smooth muscle cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 281: L816-23. PMID 11557585  1
2001 Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Research. 61: 1280-4. PMID 11245420  1
2001 Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. The Journal of Biological Chemistry. 276: 16161-7. PMID 11154688 DOI: 10.1074/jbc.M006213200  1
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-93. PMID 11426643 DOI: 10.1038/sj.onc.1204146  1
2000 Sebti SM, Hamilton AD. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene. 19: 6566-73. PMID 11426641 DOI: 10.1038/sj.onc.1204121  1
2000 Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene. 19: 5525-33. PMID 11114730 DOI: 10.1038/sj.onc.1203920  1
2000 Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 19: 5338-47. PMID 11103935 DOI: 10.1038/sj.onc.1203956  1
2000 Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion On Investigational Drugs. 9: 2767-82. PMID 11093352 DOI: 10.1517/13543784.9.12.2767  1
2000 Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, Sebti SM, Woodley DT, Imamoto A, Li W. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression Molecular Biology of the Cell. 11: 3835-3848. PMID 11071910  1
2000 Sebti SM, Hamilton AD. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. Methods in Enzymology. 325: 381-8. PMID 11036620  1
2000 Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nature Biotechnology. 18: 1065-70. PMID 11017044 DOI: 10.1038/80257  1
2000 Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. The Journal of Biological Chemistry. 275: 31001-8. PMID 10896672 DOI: 10.1074/jbc.M005264200  1
2000 Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice Journal of Biological Chemistry. 275: 17974-17978. PMID 10770919 DOI: 10.1074/jbc.C000145200  1
2000 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. Archives of Biochemistry and Biophysics. 374: 313-24. PMID 10666313 DOI: 10.1006/abbi.1999.1625  1
2000 Boota A, Johnson B, Lee KL, Blaskovich MA, Liu SX, Kagan VE, Hamilton A, Pitt B, Sebti SM, Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle American Journal of Physiology - Lung Cellular and Molecular Physiology. 278. PMID 10666117  1
2000 Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (Baltimore, Md.). 31: 131-40. PMID 10613738 DOI: 10.1002/hep.510310121  1
2000 Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 21: 113-6. PMID 10607742  1
2000 Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Molecular and Cellular Biology. 20: 139-48. PMID 10594016  1
2000 Kotharé MA, Ohkanda J, Lockman JW, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase Tetrahedron. 56: 9833-9841.  1
1999 Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic & Medicinal Chemistry. 7: 3011-24. PMID 10658608 DOI: 10.1016/S0968-0896(99)00252-7  1
1999 Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). The Journal of Biological Chemistry. 274: 33334-40. PMID 10559211 DOI: 10.1074/jbc.274.47.33334  1
1999 Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. Neurosurgery. 45: 1208-14; discussion . PMID 10549939 DOI: 10.1097/00006123-199911000-00039  1
1999 Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. Febs Letters. 460: 235-40. PMID 10544242 DOI: 10.1016/S0014-5793(99)01355-1  1
1999 Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine Cancer Research. 59: 4919-4926. PMID 10519405  1
1999 Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS Radiation Research. 152: 404-411. PMID 10477917 DOI: 10.2307/3580225  1
1999 Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I Journal of Medicinal Chemistry. 42: 1333-1340. PMID 10212118 DOI: 10.1021/jm9900873  1
1999 Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin- dependent kinase inhibitors: A potential mechanism for GGTI-298 antitumor activity Journal of Biological Chemistry. 274: 6930-6934. PMID 10066746 DOI: 10.1074/jbc.274.11.6930  1
1998 Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1- responsive element: Involvement of the small GTPase RhoA Molecular and Cellular Biology. 18: 6962-6970. PMID 9819384  1
1998 Kucich U, Rosenbloom JC, Shen G, Abrams WR, Blaskovich MA, Hamilton AD, Ohkanda J, Sebti SM, Rosenbloom J. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-β-stimulated pathway leading to elastin mRNA stabilization Biochemical and Biophysical Research Communications. 252: 111-116. PMID 9813154 DOI: 10.1006/bbrc.1998.9544  1
1998 Stark WW, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells American Journal of Physiology - Lung Cellular and Molecular Physiology. 275. PMID 9688935  1
1998 Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth Neurosurgery. 43: 124-132. PMID 9657198 DOI: 10.1097/00006123-199807000-00081  1
1998 Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics Bioorganic and Medicinal Chemistry. 6: 293-299. PMID 9568283 DOI: 10.1016/S0968-0896(97)10040-2  1
1998 Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ. Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes Cancer Research. 58: 1754-1761. PMID 9563495  1
1998 Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in node mouse xenografts Oncogene. 16: 1467-1473. PMID 9525745  1
1998 Sebti SM, Hamilton AD. New approaches to anticancer drug design based on the inhibition of farnesyltransferase Drug Discovery Today. 3: 26-33. DOI: 10.1016/S1359-6446(97)01122-7  1
1997 Sebti SM, Hamilton AD. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opinion On Investigational Drugs. 6: 1711-4. PMID 15989575 DOI: 10.1517/13543784.6.11.1711  1
1997 Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independent manner Journal of Biological Chemistry. 272: 27224-27229. PMID 9341167 DOI: 10.1074/jbc.272.43.27224  1
1997 Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy Pharmacology and Therapeutics. 74: 103-114. PMID 9336018 DOI: 10.1016/S0163-7258(97)00014-4  1
1997 Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene. 15: 1283-1288. PMID 9315095  1
1997 Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12: 229-238. PMID 9199657  1
1997 Qian Y, Sebti SM, Hamilton AD. Farnesyltransferase as a target for anticancer drug design Biopolymers. 43: 25-41. PMID 9174410  1
1997 Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2- M enrichment in A549 cells Cancer Research. 57: 1846-1850. PMID 9157972  1
1997 Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells. The Journal of Biological Chemistry. 272: 13484-8. PMID 9153192 DOI: 10.1074/jbc.272.21.13484  1
1997 Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation Journal of Biological Chemistry. 272: 10608-10615. PMID 9099708 DOI: 10.1074/jbc.272.16.10608  1
1997 McGuire TF, Sebti SM. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity Oncogene. 14: 305-312. PMID 9018116  1
1996 Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts Oncogene. 13: 1991-1999. PMID 8934546  1
1996 McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation Journal of Biological Chemistry. 271: 27402-27407. PMID 8910319 DOI: 10.1074/jbc.271.44.27402  1
1996 Sebti SM, Hamilton AD. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs Biochemical Society Transactions. 24: 692-699. PMID 8878828  1
1996 Pei Z, Sebti SM. Cys 102 and His 398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase Biochemistry. 35: 10751-10756. PMID 8718865 DOI: 10.1021/bi9605447  1
1996 Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Research. 56: 1727-1730. PMID 8620483  1
1996 Xu XQ, McGuire TF, Blaskovich MA, Sebti SM, Romero G. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts Archives of Biochemistry and Biophysics. 326: 233-237. PMID 8611028 DOI: 10.1006/abbi.1996.0070  1
1996 Qian Y, Vogt A, Sebti SM, Hamilton AD. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors Journal of Medicinal Chemistry. 39: 217-223. PMID 8568811 DOI: 10.1021/jm950414g  1
1996 Stark W, Sebti SM, Davies P. Constitutlvely active ras reduces the incidence of apoptosis in nffl 3t3 cells Faseb Journal. 10.  1
1995 Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing Journal of Biological Chemistry. 270: 660-664. PMID 7822292 DOI: 10.1074/jbc.270.2.660  1
1995 Sun J, Sebti SM, Qian Y, Hamilton AD. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion Cancer Research. 55: 4243-4247. PMID 7671229  1
1995 McGuire TF, Qian Y, Blaskovich MA, Fossum RD, Sun J, Marlowe T, Corey SJ, Wathen SP, Vogt A, Hamilton AD. CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochemical and Biophysical Research Communications. 214: 295-303. PMID 7669049 DOI: 10.1006/bbrc.1995.2287  1
1995 Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes Journal of Biological Chemistry. 270: 26802-26806. PMID 7592920 DOI: 10.1074/jbc.270.45.26802  1
1995 Lernert EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor Journal of Biological Chemistry. 270: 26770-26773. PMID 7592913 DOI: 10.1074/jbc.270.45.26770  1
1995 Sebti SM. Burkitt lymphoma daudi cells contain two distinct farnesyltransferases with different divalent cation requirements Biochemistry. 34: 12398-12403. PMID 7547984  1
1995 Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 92: 10919-23. PMID 7479910 DOI: 10.1073/pnas.92.24.10919  1
1995 Pei Z, Calmels TPG, Creutz CE, Sebti SM. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells Molecular Pharmacology. 48: 676-681. PMID 7476893  1
1995 Hamilton AD, Sebti SM. Inhibitors of ras farnesyltransferase as novel antitumor agents Drug News and Perspectives. 8: 138-145.  1
1994 Weng W, Reynolds IJ, Jani JP, Blaskovich M, Sebti SM, Davies P, Pitt BR. Desensitization of 5HT2 receptors by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture. Microcirculation (New York, N.Y. : 1994). 1: 129-35. PMID 8790584 DOI: 10.3109/10739689409148268  1
1994 Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase Journal of Biological Chemistry. 269: 12410-12413. PMID 8175645  1
1994 Lazo JS, Sebti SM. Bleomycin Cancer Chemotherapy and Biological Response Modifiers. 15: 44-50. PMID 7540032  1
1994 Mcguire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin Disrupts Early Events in Insulin Signaling: A Potential Mechanism of Lovastatins Anti-Mitogenic Activity Biochemical and Biophysical Research Communications. 204: 399-406. PMID 7524501 DOI: 10.1006/bbrc.1994.2472  1
1994 Qian Y, Blaskovich MA, Seong CM, Vogt A, Hamilton AD, Sebti SM. Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells Bioorganic and Medicinal Chemistry Letters. 4: 2579-2584. DOI: 10.1016/S0960-894X(01)80287-0  1
1993 Nigam M, Seong CM, Qian Y, Hamilton AD, Sebti SM. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. The Journal of Biological Chemistry. 268: 20695-8. PMID 8407887  1
1993 McGuire TF, Corey SJ, Sebti SM. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor Journal of Biological Chemistry. 268: 22227-22230. PMID 7693661  1
1992 Morris G, Mistry JS, Jani JP, Mignano JE, Sebti SM, Lazo JS. Neutralization of bleomycin hydrolase by an epitope-specific antibody. Molecular Pharmacology. 42: 57-62. PMID 1378925  1
1992 Jani JP, Mistry JS, Morris G, Lazo JS, Sebti SM. In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncology Research. 4: 59-63. PMID 1375852  1
1992 Mistry JS, Jani JP, Morris G, Mujumdar RB, Reynolds IJ, Sebti SM, Lazo JS. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. Cancer Research. 52: 709-18. PMID 1370650  1
1991 Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice Cancer Communications. 3: 141-147. PMID 2043425  1
1991 Lazo JS, Sebti SM. Bleomycins Cancer Chemotherapy and Biological Response Modifiers. 12: 51-58. PMID 1718378  1
1991 Morris G, Mistry JS, Jani JP, Sebti SM, Lazo JS. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochemical Pharmacology. 41: 1559-66. PMID 1710457 DOI: 10.1016/0006-2952(91)90154-W  1
1991 Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Research. 51: 227-32. PMID 1703034  1
1990 Lazo JS, Hoyt DG, Sebti SM, Pitt BR. Bleomycin: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis Pharmacology and Therapeutics. 47: 347-358. PMID 1705351 DOI: 10.1016/0163-7258(90)90061-6  1
1990 Mistry JS, Sebti SM, Lazo JS. Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography. Journal of Chromatography. 514: 86-90. PMID 1698802 DOI: 10.1016/S0021-9673(01)89380-8  1
1989 Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS. Bleomycin hydrolase: Molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family Biochemistry. 28: 6544-6548. PMID 2477059  1
1989 Sebti SM, Deleon JC, Ma LT, Hecht SM, Lazo JS. Substrate specificity of bleomycin hydrolase Biochemical Pharmacology. 38: 141-147. PMID 2462878 DOI: 10.1016/0006-2952(89)90160-3  1
1988 Sebti SM, Lazo JS. Metabolic inactivation of bleomycin analogs by bleomycin hydrolase Pharmacology and Therapeutics. 38: 321-329. PMID 2461572 DOI: 10.1016/0163-7258(88)90009-5  1
1987 Sebti SM. Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase Biochemistry. 26: 4213-4219. PMID 3117099  1
1987 Sebti SM, Lazo JS. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases Biochemistry. 26: 432-437. PMID 3103681  1
1986 Baird WM, Sebti SM, Reinsvold LA. Metabolic activation of benzo(a)pyrene in SENCAR and BALB/c mouse embryo cell cultures Environmental Health Perspectives. 45-52. PMID 3780631  1
1985 Sebti SM, Pruess-Schwartz D, Baird WM. Species- and Length of Exposure-dependent Differences in the Benzo(a)pyrene:DNA Adducts Formed in Embryo Cell Cultures from Mice, Rats, and Hamsters Cancer Research. 45: 1594-1600. PMID 3978626  1
1985 Sebti SM, Smolarek TA, Salmon CP, Baird WM. 7,12-Dimethylbenz[a]anthracene-DNA adduct formation in Wistar rat and Syrian hamster embryo cell cultures Chemico-Biological Interactions. 56: 1-12. PMID 3935336 DOI: 10.1016/0009-2797(85)90035-3  1
1984 Pruess-Schwartz D, Sebti SM, Gilham PT, Baird WM. Analysis of benzo(a)pyrene:DNA adducts formed in cells in culture by immobilized boronate chromatography Cancer Research. 44: 4104-4110. PMID 6331665  1
1984 Sebti SM, Baird WM. Rat liver homogenate (S9)-mediated binding of benzo[a]pyren to DNA in V79 cells, V79 cell nuclei and aqueous solution Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 125: 307-314. PMID 6321977 DOI: 10.1016/0027-5107(84)90080-0  1
Show low-probability matches.